24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500

Medical Disorders
Basic InformationLookupsLatest News
Lung Diseases on the Rise WorldwideNew China Coronavirus Cases Decline, 2 Passengers From Affected Cruise Ship DieAHA News: What Women Need to Know About Breast Cancer and Heart DiseaseU.S. Scientists Take Key Step Towards Towards Coronavirus VaccineQuarantine Ends on Cruise Ship in Japan as Coronavirus Cases Near 75,000AHA News: Race and Gender May Tip the Scales on Traditional Stroke Risk FactorsMeasles Complications Can Affect Every Organ: StudyBabies' Exposure to Household Cleaning Products Tied to Later Asthma RiskCoronavirus: Are U.S. Hospitals Prepared?14 Americans From Cruise Ship Hit By Coronavirus Test Positive for InfectionHot Chocolate Could Help Ease Painful Clogged Leg VesselsAntiviral Drug, Plasma Transfusions Show Promise in Treating CoronavirusHow to Dispel Your Child's Fears About the New CoronavirusCholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCoronavirus Spreads Most Easily When Patients Are Sickest: CDCWill Brushing and Flossing Protect You Against Stroke?Young Black Adults More Prone to Stroke, but Don't Know ItAHA News: Stroke Rates Down for Mexican Americans, Up for White AdultsCoronavirus Cases, Deaths Rise Sharply, While 2 New Cases Reported in U.S.Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune DisordersCoronavirus in America: Keep Your Panic in CheckCoronavirus Spread Slows, But Death Toll Jumps to 1,113Growing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeShingles Vaccine Bonus: Reduced Risk of Stroke?Air Pollution Made in One State Can Cause Deaths in OthersWere You Born in an H1N1 Flu Year or an H3N2? It MattersStricter Clean Air Laws Could Save Thousands of Lives a Year: StudyCoronavirus Fears Have U.S. Pharmacies Running Out of Face MasksCoronavirus Death Toll Tops 1,000, While 13th U.S. Case ConfirmedMeds May Not Prevent Migraines in KidsHigh Testosterone Levels Have Different Health Impact for Men and WomenCoronavirus Cases Top 40,000, While Deaths Hit 908With Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision LossHundreds Suspected, 12 Confirmed: How CDC Identified U.S. Coronavirus CasesFor Patients on Blood Thinners, GI Bleeding May Signal Colon Cancer: StudyStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsThere's a Virus Spreading in U.S. That's Killed 10,000: The FluSome U.S. Workers Are Bringing Toxins Home to Their KidsAHA News: Expert Heart Advice for Rare Genetic Muscle Disorder9/11 Study Shows PTSD Tied to Earlier DeathWorkers With Cluster Headaches Take Twice as Many Sick DaysMore Americans to Be Evacuated From China; 12th Coronavirus Case ReportedYoung-Onset Parkinson's May Start in the Womb, New Research SuggestsHealthy Habits Can Slide After Starting Heart MedicationsWide Variations Found in 'Normal' Resting Heart RateLab Discovery Offers Promise for Treating Multiple SclerosisIs Vaping a Scourge on Your Skin?Many Can Suffer Facial Paralysis -- and Its Emotional TollAHA News: Persistent Asthma Linked to Increased Risk for Heart Rhythm DisorderAs Health Experts Fear Possible Pandemic, 2nd Death Reported Outside China
Questions and AnswersLinks
Related Topics


Drug Duo May Be an Advance Against a Common Leukemia

HealthDay News
by -- Robert Preidt
Updated: Jul 31st 2019

new article illustration

WEDNESDAY, July 31, 2019 (HealthDay News) -- A two-drug combo helps patients with a common form of leukemia survive longer than the current standard of care, a new clinical trial finds.

The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.

Specifically, 89.4% of the patients who received the experimental drug combination did not have any progression of their leukemia about three years after treatment, compared with 72.9% of those who received the traditional chemotherapy combination.

As to overall survival, regardless of whether the disease had progressed or not, the trial found that three years after treatment, 98.8% of patients who received the two-drug combination were alive, compared with 91.5% of those who received the traditional treatment.

The research was led by Dr. Tait Shanafelt, professor of medicine at Stanford University, and will be published Aug. 1 in the New England Journal of Medicine. The study received funding from Pharmacyclics LLC, which makes ibrutinib.

Shanafelt and his team believe the results could change how most people with CLL are treated.

"These results will fully usher the treatment of chronic lymphocytic leukemia into a new era," Shanafelt said in a Stanford news release.

"We've found that this combination of targeted treatments is both more effective and less toxic than the previous standard of care for these patients," he added. "It seems likely that, in the future, most patients will be able to forgo chemotherapy altogether."

Patient Dan Rosenbaum, 57, was one of the participants randomly assigned to receive the dual drug treatment. In the news release, he said he felt an easing of symptoms very soon after the therapy began.

"I hadn't realized how fatigued I had become," Rosenbaum said. "I could barely play a single set of tennis, and I would be wiped out for days afterward. My lymph nodes were so swollen it was impossible to button the top button of my shirt collar. But within the first week of starting treatment, I noticed I had a little more spring in my step. After 10 days, there was a marked improvement in the size of my lymph glands. And after six weeks, my tumors were no longer detectable by physical exam."

The current standard treatment for CLL patients is an intravenous combination of three drugs -- fludarabine, cyclophosphamide and rituximab (FCR). Fludarabine and cyclophosphamide kill both healthy and cancerous cells by interfering with DNA replication, while rituximab targets immune system B cells that "run amok" in CLL, according to the researchers.

However, fludarabine and cyclophosphamide can cause significant side effects such as severe blood complications and life-threatening infections, the researchers said.

The new drug combination pairs rituximab with ibrutinib, which also specifically targets B cells.

"This is one of those situations we don't often have in oncology," Shanafelt explained. "The new treatment is both more effective and better tolerated. This represents a paradigm shift in how these patients should be treated. We can now relegate [traditional] chemotherapy to a fallback plan rather than a first-line course of action."

One expert in CLL care agreed that the findings might mark an advance.

"The major strength of this study is that it is a prospectively randomized comparison with the 'chemo-immunotherapy' combination FCR, in a large sample size," said Dr. Kanti Rai. He's a hematologist with the CLL Research and Treatment Program at Northwell Health Cancer Institute in New Hyde Park, N.Y.

The new study finds that the two-drug combo is now "superior" to the three-drug approach, Rai said. However, FCR might still work best in a subgroup of CLL patients whose cancer has certain genetic characteristics, he added.

More information

The American Cancer Society has more on CLL.